Patents by Inventor Tetsuo Mashima

Tetsuo Mashima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11415584
    Abstract: The therapeutic effect of and/or prognosis after administration of an anti-VEGFR-2 antibody drug, in particular, ramucirumab can be predicted by measuring VEGF-A, VEGF-D, sVEGFR-2, SDF-1?, and/or cNRP1. Provided is a biomarker for predicting the effect of administration of the anti-VEGFR-2 antibody drug, in particular, ramucirumab, and a test method and a test kit using the marker.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: August 16, 2022
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Tetsuo Mashima, Takeru Wakatsuki, Hiroyuki Seimiya, Kensei Yamaguchi
  • Publication number: 20200355699
    Abstract: The therapeutic effect of and/or prognosis after administration of an anti-VEGFR-2 antibody drug, in particular, ramucirumab can be predicted by measuring VEGF-A, VEGF-D, sVEGFR-2, SDF-1?, and/or cNRP1. Provided is a biomarker for predicting the effect of administration of the anti-VEGFR-2 antibody drug, in particular, ramucirumab, and a test method and a test kit using the marker.
    Type: Application
    Filed: December 27, 2017
    Publication date: November 12, 2020
    Inventors: Tetsuo Mashima, Takeru Wakatsuki, Hiroyuki Seimiya, Kensei Yamaguchi
  • Publication number: 20090202569
    Abstract: The present invention provides a preventative/therapeutic agent for cancer capable of selectively and effectively killing cancer cells. A medicament of the present invention prepared by combining at least one selected from a substance that inhibits the activity of an enzyme belonging to the acyl-CoA synthase family and a substance that inhibits expression of a gene for an enzyme belonging to the acyl-CoA synthase family, with at least one selected from a substance that inhibits the activity of fatty acid synthase and a substance that inhibits expression of a fatty acid synthase gene and the like can be used as a preventative/therapeutic agent for cancer capable of selectively and effectively killing cancer cells.
    Type: Application
    Filed: April 6, 2007
    Publication date: August 13, 2009
    Inventors: Tetsuo Mashima, Takashi Tsuruo, Hideaki Tojo, Hiroyuki Sumi
  • Publication number: 20090155241
    Abstract: A compound or its salt that inhibits the activity of a protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1; a compound or its salt that inhibits the expression of a gene for the protein; an antisense polynucleotide comprising a nucleotide sequence complementary or substantially complementary to the nucleotide sequence of a polynucleotide encoding the protein or a partial peptide thereof or a part of the nucleotide sequence; an antibody against the protein; etc. are useful as preventive/therapeutic agents for cancer, apoptosis promoters for cancer cells, or the like.
    Type: Application
    Filed: July 22, 2005
    Publication date: June 18, 2009
    Inventors: Tetsuo Mashima, Takashi Tsuruo